Symbion Discovery, Inc. is a company dedicated to the research and development of new therapeutics. The firm's primary interest is in finding antimicrobials - particularly cyanobactins that act as antibiotics on MRSAs or other health-care associated infections, or tuberculosis, or as anti-virals to combat HIV or flu viruses, or anti-fungals to treat yeast infections. Cyanobactins are also known to have chemotherapeutic activity, and this is another area of interest for Symbion Discovery. The key is to harness the cyanobactinâs toxic characteristics and use them to selectively kill bacteria or virus or fungus or cancer cells.
